WATERTOWN, Mass., Sept. 6 /PRNewswire-FirstCall/ -- Panacos Pharmaceuticals, Inc. (“Panacos” or “the Company”), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, has been invited to speak at the Bear Stearns Annual Healthcare Conference, to be held at The Grand Hyatt Hotel in New York City on Monday, September 12, 2005. Panacos’ presentation is scheduled to begin that day at 8:00 a.m., Eastern Daylight Time. Dr. Samuel K. Ackerman, President and CEO of Panacos, will present.
A link to the live webcast of Panacos’ presentation will be available on the Company’s Web site at http://www.panacos.com. The webcast link to access a replay of the presentation will be archived and available through Monday, September 19, 2005.
About Panacos Pharmaceuticals
Panacos, formerly known as V. I. Technologies, Inc. or VITEX, is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Panacos’ proprietary discovery technologies and lead therapeutic candidate PA-457 focus on novel targets in the virus life cycle, including virus fusion and virus maturation. For more information on Panacos, please visit our web site at: http://www.panacos.com.
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, such as the progress of clinical development of PA-457, including the Company’s plan to initiate a Phase 2b study in the first half of 2006, and the timing of results of clinical trials, the execution of the Company’s financing plans, the potential role of PA-457 in treatment of HIV patients, the timely availability of new products, market acceptance of the Company’s products, the impacts of competitive products and pricing, government regulation of the Company’s products, the Company’s ability to complete product development collaborations and other strategic transactions and other risks and uncertainties set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
CONTACT: Peyton Marshall Executive Vice President & CFO 617-926-1551 pmarshall@panacos.com
Panacos Pharmaceuticals, Inc.
CONTACT: Peyton Marshall, Executive Vice President & CFO of PanacosPharmaceuticals, Inc., +1-617-926-1551, pmarshall@panacos.com
Web site: http://www.panacos.com//
